Portilla-Martínez A, Ortiz-Flores M, Hidalgo I, González-Ruiz C, Ceballos G, Nájera N

Language: English
References: 12
Page: 66-70
PDF size: 195.31 Kb.

ABSTRACT

There are several theories of how a drug interacts with a receptor. This review discuss the theories considered the most relevant to elucidate the mechanisms that govern drug-receptor interactions such as the occupational theory proposed by A. J. Clark, who stablished that drug-receptor interactions can be interpreted as processes that obey the laws of physics and chemistry, proposing for the first time a mathematical approach describing the behavior of a ligand-receptor interaction. This theory has been modified with the development of new technics, such as recombinant technology, protein crystallization and in silico methodologies, which all contribute with important experimental data for a better understanding of ligand-receptor interaction. Over time the drug-receptor interactions theories became more complex and accurate, and gain a few fundamental parameters such as potency, efficacy, dose, types of agonism (partial, total, inverse), antagonism (competitive and non-competitive) or modulation. The deep understanding of these new concepts in drug-receptor pharmacology, can make the difference between success or failure in pharmacological treatment in the clinical area.

REFERENCES

1. Whyte Black J, Leff P. Operational models of pharmacological agonism. Proc R Soc London Ser B Biol Sci [Internet]. 1983; 220 (1219): 141-162. Available from: https://royalsocietypublishing.org/doi/10.1098/rspb.1983.0093

2. Kenakin T. Principles: receptor theory in pharmacology. Trends Pharmacol Sci [Internet]. 2004; 25 (4): 186-192. Available from: https://linkinghub.elsevier.com/retrieve/pii/S016561470400063X

3. Maehle AH, Prüll CR, Halliwell RF. The emergence of the drug receptor theory. Nat Rev Drug Discov [Internet]. 2002; 1 (8): 637-641. Available from: http://www.nature.com/articles/nrd875

4.  . Park PS, Lodowski DT, Palczewski K. Activation of G protein–coupled receptors: beyond two-state models and tertiary conformational changes. Annu Rev Pharmacol Toxicol [Internet]. 2008 [cited 2020 Feb 7]; 48 (1): 107-141. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17848137

5. Clark AJ. General pharmacology [Internet]. Berlin, Heidelberg: Springer Berlin Heidelberg; 1970. Available from: http://link.springer.com/10.1007/978-3-642-80555-4

6. Maehle AH. A binding question: the evolution of the receptor concept. Endeavour [Internet]. 2009; 33 (4): 135-140. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0160932709000672

7. Sigg D. Modeling ion channels: past, present, and future. J Gen Physiol [Internet]. 2014; 144 (1): 7-26. Available from: https://rupress.org/jgp/article/144/1/7/43381/Modeling-ion-channels-Past-present-and

8. Chan HCS, Filipek S, Yuan S. The principles of ligand specificity on beta-2-adrenergic receptor. Sci Rep [Internet]. 2016; 6 (1): 34736. Available from: http://www.nature.com/articles/srep34736

9. Kenakin TP. Chapter 4 - Drug antagonism: orthosteric drug effects. In: Kenakin TP. Pharmacology in drug discovery and development [Internet]. 2nd edition. San Diego, CA: Academic Press; 2017. pp. 65-100. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9780128037522000041

10. Keating GM, Jarvis B. Carvedilol. Drugs [Internet]. 2003; 63 (16): 1697-1741. Available from: http://link.springer.com/10.2165/00003495-200363160-00006

11. Poirier L, Lacourcičre Y. The evolving role of β-adrenergic receptor blockers in managing hypertension. Can J Cardiol [Internet]. 2012; 28 (3): 334-340. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0828282X12001870

12. Ferguson SSG, Feldman RD. β-Adrenoceptors as molecular targets in the treatment of hypertension. Can J Cardiol [Internet]. 2014; 30 (5): S3-S8. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0828282X14000695